Embolization Particle Market - Market Dynamics
The market for embolization particle is driven by factors such as increasing prevalence of various types of cancer.
Embolization particles are the crucial product used in the treatment of malignancies such as cancer, peripheral diseases, and others. Rising prevalence of cancer globally, has supported growth of the embolization particle market. According to World Health Organization (WHO), cancer is the second prominent cause of death across the globe, and around 9.6 million deaths occurred due to cancer in 2018. Moreover, as per the Cancer Research UK, over 17 million new cases were estimated to occur in year 2018 around the globe. The burden of cancer is increasing rapidly in the U.S. with the incidence of 439.2 per 100,000 men and women per year as according to National Cancer Institute (2015).
Moreover, major players are constantly introducing technologically advanced products with improved efficiency that supports growth of the embolization particle market. For instance, in 2017, Sirtex introduced SIR-Spheres Y-90 resin microspheres, which serves as first-line treatment for patients with liver metastases from right-sided primary colon cancer. In 2016, UK National Institute for Health and Care Excellence (NICE) issued a new update stating that National Health Service (NHS) doctors and commissioners may consider Sirtex’s SIR-Spheres Y-90 resin microspheres as an alternative to standard therapy with trans-arterial chemoembolization (TACE) or sorafenib in the treatment of patients with inoperable primary liver cancer.
Market Trends
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients